| Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics |
47 |
| Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation |
35 |
| Orthogonal Comparison of Four Plasma NGS Tests With Tumor Suggests Technical Factors are a Major Source of Assay Discordance |
35 |
| Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion |
33 |
| Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types |
33 |
| Cholangiocarcinoma With FGFR Genetic Aberrations: A Unique Clinical Phenotype |
25 |
| Use of Next-Generation Sequencing Tests to Guide Cancer Treatment: Results From a Nationally Representative Survey of Oncologists in the United States |
23 |
| Stromal Content Is Correlated With Tissue Site, Contrast Retention, and Survival in Pancreatic Adenocarcinoma |
19 |
| Majority of B2M-Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High |
18 |
| Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors Through Longitudinal Analysis of Circulating Tumor DNA |
18 |
| Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors |
17 |
| Clinical Value of RNA Sequencing-Based Classifiers for Prediction of the Five Conventional Breast Cancer Biomarkers: A Report From the Population-Based Multicenter Sweden Cancerome Analysis Network-Breast Initiative |
16 |
| Acquired ALK and RET Gene Fusions as Mechanisms of Resistance to Osimertinib in EGFR-Mutant Lung Cancers |
15 |
| Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers |
13 |
| Clinical Utility of Gene Expression Classifiers in Men With Newly Diagnosed Prostate Cancer |
13 |
| Rationale and Design of the Targeted Agent and Profiling Utilization Registry Study |
13 |
| Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene Mutations |
13 |
| Economic Impact of Next-Generation Sequencing Versus Single-Gene Testing to Detect Genomic Alterations in Metastatic Non-Small-Cell Lung Cancer Using a Decision Analytic Model |
12 |
| Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in BRCA2-Associated Prostate Cancer Resulting From Biallelic BRCA2 Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations |
11 |
| Analysis of MDM2 Amplification: Next-Generation Sequencing of Patients With Diverse Malignancies |
11 |
| Genetic Alterations Detected in Cell-Free DNA Are Associated With Enzalutamide and Abiraterone Resistance in Castration-Resistant Prostate Cancer |
11 |
| Mismatch Repair Deficiency in High-Grade Meningioma: A Rare but Recurrent Event Associated With Dramatic Immune Activation and Clinical Response to PD-1 Blockade |
11 |
| Detection of Early Human Papillomavirus-Associated Cancers by Liquid Biopsy |
11 |
| Real-World Utility of an Amplicon-Based Next-Generation Sequencing Liquid Biopsy for Broad Molecular Profiling in Patients With Advanced Non-Small-Cell Lung Cancer |
10 |
| Influence of TP53 Mutation on Survival in Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer |
10 |
| Genomic Assessment of Blood-Derived Circulating Tumor DNA in Patients With Colorectal Cancers: Correlation With Tissue Sequencing, Therapeutic Response, and Survival |
10 |
| Transcriptional Subtyping and CD8 Immunohistochemistry Identifies Patients With Stage II and III Colorectal Cancer With Poor Prognosis Who Benefit From Adjuvant Chemotherapy |
9 |
| Tumor Mutational Burden Is Site Specific in Non-Small-Cell Lung Cancer and Is Highest in Lung Adenocarcinoma Brain Metastases |
9 |
| epiCaPture: A Urine DNA Methylation Test for Early Detection of Aggressive Prostate Cancer |
9 |
| Comparative Analysis of Durable Responses on Immune Checkpoint Inhibitors Versus Other Systemic Therapies: A Pooled Analysis of Phase III Trials |
9 |
| Real-Time Genomic Characterization of Metastatic Pancreatic Neuroendocrine Tumors Has Prognostic Implications and Identifies Potential Germline Actionability |
8 |
| Circulating Tumor DNA Profiling of Advanced Biliary Tract Cancers |
8 |
| Retrospective Survival Analysis of Patients With Advanced Pancreatic Ductal Adenocarcinoma and Germline BRCA or PALB2 Mutations |
8 |
| Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer |
8 |
| Impact of KRAS and TP53 Co-Mutations on Outcomes After First-Line Systemic Therapy Among Patients With STK11-Mutated Advanced Non-Small-Cell Lung Cancer |
8 |
| Aggressive-Variant Microsatellite-Stable POLE Mutant Prostate Cancer With High Mutation Burden and Durable Response to Immune Checkpoint Inhibitor Therapy |
8 |
| Comparison of Treatment Recommendations by Molecular Tumor Boards Worldwide |
8 |
| ALK Testing Trends and Patterns Among Community Practices in the United States |
8 |
| First Report of Clinical Response to Venetoclax in Early T-Cell Precursor Acute Lymphoblastic Leukemia |
8 |
| Efficacy of Vemurafenib in Patients With Non-Small-Cell Lung Cancer With BRAF V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study |
7 |
| Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer |
7 |
| Molecular Characterization and Clinical Outcomes of Primary Gleason Pattern 5 Prostate Cancer After Radical Prostatectomy |
7 |
| Complete and Prolonged Response to Immune Checkpoint Blockade in POLE-Mutated Colorectal Cancer |
7 |
| Detection of Somatic Structural Variants Enables Quantification and Characterization of Circulating Tumor DNA in Children With Solid Tumors |
7 |
| Genomic Landscape of Appendiceal Neoplasms |
7 |
| Validation of HER2 Amplification as a Predictive Biomarker for Anti-Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer |
7 |
| Prospective Clinical Validation of the InVisionFirst-Lung Circulating Tumor DNA Assay for Molecular Profiling of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer |
7 |
| Plasma Cell-Free DNA Testing of Patients With EGFR Mutant Non-Small-Cell Lung Cancer: Droplet Digital PCR Versus Next-Generation Sequencing Compared With Tissue-Based Results |
7 |
| Personalized Clinical Decision Making Through Implementation of a Molecular Tumor Board: A German Single-Center Experience |
7 |
| Evaluation of Commercial Circulating Tumor DNA Test in Metastatic Prostate Cancer |
7 |
